Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant bemosubaimab + anlotinib in locally advanced or unresectable clear cell renal cell carcinoma
ChiCTR2600126420Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemosubaimab and anlotinib in clear cell renal cell carcinoma (ccRCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bemosubaimabanlotinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2600126420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126420.